Candesartan cilexetil - Takeda

Drug Profile

Candesartan cilexetil - Takeda

Alternative Names: Amias; Atacand; Blopress; Candesartan hexetil; Kenzen; Parapres; Ratacand; TCV-116; Tiadyl

Latest Information Update: 26 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer Netherlands Cancer Institute; Takeda
  • Class Antihypertensives; Benzimidazoles; Heart failure therapies; Tetrazoles
  • Mechanism of Action Angiotensin type 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Hypertension
  • No development reported Cardiovascular disorders
  • Discontinued Coronary artery restenosis; Diabetic nephropathies; Diabetic retinopathy; Glomerulonephritis

Most Recent Events

  • 24 Jul 2018 Cheplapharm Arzneimittel acquires commercial rights to candesartan cilexetil for Heart failure and Hypertension in Europe
  • 24 Jun 2018 Biomarkers information updated
  • 16 Jun 2017 Updated efficacy data from the TROPHY trial in Hypertension presented at the 27th European Meeting on Hypertension and Cardiovascular Protection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top